projectstartups.com

Rege Nephro

Rege Nephro Co., Ltd. is a clinical-stage biotech company developing therapeutics and cell therapy for kidney, liver, and pancreas diseases using induced pluripotent stem cell (iPSC)-based technology from Kyoto University's CiRA. Their current focus is on RN-014 for ADPKD and RN-032 for CKD.


Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $15M

Date: 08-Oct-2024

Investors: DCI Partners Co., Ltd., JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC

Markets: Biotechnology, Pharmaceuticals, Cell Therapy, Biotechnology Research

HQ: Kyoto, Kyoto Prefecture, Japan

Founded: 2019

Website: https://www.regenephro.co.jp/en

LinkedIn: https://www.linkedin.com/company/rege-nephro

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/rege-nephro?utm_source=linkedin&utm_medium=referral&utm_campaign=linkedin_companies&utm_content=profile_cta_anon&trk=funding_crunchbase

Pitchbook: https://pitchbook.com/profiles/company/464198-41

Download Funded Startups lists

Leave a Comment